<DOC>
	<DOCNO>NCT01520688</DOCNO>
	<brief_summary>Children mild persistent asthma asthma symptom twice week use daily controller , child mild intermittent asthma rarely asthma symptom use daily controller . Inhaled corticosteroid standard treatment mild peristent asthma . The purpose study measure child rate growth different inhaled corticosteroid .</brief_summary>
	<brief_title>Effect Flovent Discus v QVAR v Pulmicort Flexhaler Short Term Growth</brief_title>
	<detailed_description>A randomize , cross study evaluate effect Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID short term growth pediatric subject asthma . Objectives : 1 . The primary objective study compare effect Flovent Diskus 100 mcg BID versus Pulmicort Flexhaler 180 mcg BID short-term low leg growth velocity measure knemometry pediatric subject mild asthma . 2 . The secondary objective study compare effect Flovent Diskus 100 mcg BID versus QVAR 80 mcg BID short-term low leg growth velocity measure knemometry pediatric subject mild asthma . Aims : 1 . The primary aim show growth suppressive effect Pulmicort Flexhaler 180 mcg BID versus Flovent Diskus 100 mcg BID child mild asthma . 2 . The secondary aim show growth suppressive effect QVAR 80 mcg BID versus Flovent Diskus 100 mcg BID child mild asthma . Hypotheses : 1 . The primary hypothesis treatment Pulmicort Flexhaler 180mcg BID compare Flovent Diskus 100 mcg BID growth suppressive effect lower leg length assess knemometry pediatric subject mild asthma . 2 . The secondary hypothesis treatment QVAR 80 mcg BID compare Flovent Diskus 100 mcg BID growth suppressive effect lower leg length assess knemometry pediatric subject mild asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Subjects include female ( 6 9 year age ) male ( 6 11 year age ) . 2 . All subject must history physician diagnose mild intermittent mild persistent asthma document PCP medical record detail history study investigator . 3 . All subject must height within normal limit ( 5th 95th percentile ) history abnormal growth assess medical history . 4 . All subject must prepubertal ( Tanner Stage 1 Sexual Maturity ) assess physical examination . 5 . Subjects may current treatment montelukast drug affect growth . If subject montelukast screening/baseline , remain stable dose throughout study . 6 . Subjects must willing comply study requirement . 1 . Subjects exclude asthma great mild persistent severity define NHLBI guideline . 2 . Subjects exclude used systemic nasal steroid within past 60 day . 3 . Subjects exclude one burst systemic steroid within past year . 4 . Subjects exclude baseline FEV1 &lt; 80 % predict . 5 . Subjects exclude serious systemic disease asthma . 6 . Subjects exclude take medication know affect growth i.e . ADHD medication within past 60 day 7 . Subjects exclude history allergy study medication , milk protein lactose . 8 . Subjects exclude active chickenpox measles recent exposure chickenpox measles . 9 . Subjects exclude history tuberculosis respiratory tract . 10 . Subjects exclude active fungal , bacterial , viral parasitic infection . 11 . Subjects exclude history herpes simplex infection eye . 12 . Subjects exclude take immunosuppressive drug within past 2 month . 13 . Subjects exclude history ChurgStrauss syndrome eosinophilic disorder . 14 . Subjects exclude investigator deems mental development health issue , autism , moderate severe mental retardation severe ADHD , interfere ability complete knemometry measurement . 15 . Subjects exclude investigator deems physical issue , inability sit independently amputation low leg , interfere ability complete knemometry measurement .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mild persistent mild intermittent asthma</keyword>
</DOC>